Terms: = Ovarian cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
109 results:
1. Armored TGFβRIIDN ROR1-car T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
2. Efficient car T cell targeting of the CA125 extracellular repeat domain of MUC16.
Casey NP; Kleinmanns K; Forcados C; Gelebart PF; Joaquina S; Lode M; Benard E; Kaveh F; Caulier B; Helgestad Gjerde C; García de Jalón E; Warren DJ; Lindemann K; Rokkones E; Davidson B; Myhre MR; Kvalheim G; Bjørge L; McCormack E; Inderberg EM; Wälchli S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604812
[TBL] [Abstract] [Full Text] [Related]
3. Immunotherapy for ovarian cancer: Disappointing or Promising?
Deng M; Tang F; Chang X; Liu P; Ji X; Hao M; Wang Y; Yang R; Ma Q; Zhang Y; Miao J
Mol Pharm; 2024 Feb; 21(2):454-466. PubMed ID: 38232985
[TBL] [Abstract] [Full Text] [Related]
4. car-T cell immunotherapy for ovarian cancer: hushing the silent killer.
Nasiri F; Farrokhi K; Safarzadeh Kozani P; Mahboubi Kancha M; Dashti Shokoohi S; Safarzadeh Kozani P
Front Immunol; 2023; 14():1302307. PubMed ID: 38146364
[TBL] [Abstract] [Full Text] [Related]
5. [Killing effect of anti-MSLN-icar-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
[No Abstract] [Full Text] [Related]
6. Pyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment.
Wang A; Wang Y; Du C; Yang H; Wang Z; Jin C; Hamblin MR
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189058. PubMed ID: 38113952
[TBL] [Abstract] [Full Text] [Related]
7. Hypoxic 3D Tumor Model for Evaluating of car-T Cell Therapy In Vitro.
Oh JM; Shen K
Methods Mol Biol; 2024; 2748():119-134. PubMed ID: 38070112
[TBL] [Abstract] [Full Text] [Related]
8. CD44v6 specific car-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
[TBL] [Abstract] [Full Text] [Related]
9. Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and car/IL-15 engineering.
Lee D; Dunn ZS; Guo W; Rosenthal CJ; Penn NE; Yu Y; Zhou K; Li Z; Ma F; Li M; Song TC; Cen X; Li YR; Zhou JJ; Pellegrini M; Wang P; Yang L
Nat Commun; 2023 Nov; 14(1):6942. PubMed ID: 37938576
[TBL] [Abstract] [Full Text] [Related]
10. Engineering strategies to optimise adoptive cell therapy in ovarian cancer.
Guerra C; Kalaitsidou M; Kueberuwa G; Hawkins R; Edmondson R
Cancer Treat Rev; 2023 Dec; 121():102632. PubMed ID: 37837788
[TBL] [Abstract] [Full Text] [Related]
11. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression.
Jiang W; Gu G; Zhang Y; Song Y; Shi M; Wang G; Li H; Tao T; Qin J; Li X; Jia H; Jiao F; Xu W; Huang X
Pharmacol Res; 2023 Nov; 197():106942. PubMed ID: 37775021
[TBL] [Abstract] [Full Text] [Related]
12. Nanoscale car Organization at the Immune Synapse Correlates with car-T Effector Functions.
Sajman J; Yakovian O; Unger Deshet N; Almog S; Horn G; Waks T; Globerson Levin A; Sherman E
Cells; 2023 Sep; 12(18):. PubMed ID: 37759484
[TBL] [Abstract] [Full Text] [Related]
13. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
[TBL] [Abstract] [Full Text] [Related]
14. Highly proliferative and hypodifferentiated car-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
[TBL] [Abstract] [Full Text] [Related]
15. Myeloid-Derived Suppressor Cells (MDSCs) in ovarian cancer-Looking Back and Forward.
Okła K
Cells; 2023 Jul; 12(14):. PubMed ID: 37508575
[TBL] [Abstract] [Full Text] [Related]
16. A novel TREM1/DAP12-based multiple chain car-T cell targets PTK7 in ovarian cancer therapy.
Xu T; Wang C; Wang X; Wang E; Wang B; Sun M
Med Oncol; 2023 Jul; 40(8):226. PubMed ID: 37405498
[TBL] [Abstract] [Full Text] [Related]
17. Single car-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040
[TBL] [Abstract] [Full Text] [Related]
18. Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus.
Taha Z; Crupi MJF; Alluqmani N; Fareez F; Ng K; Sobh J; Lee E; Chen A; Thomson M; Spinelli MM; Ilkow CS; Bell JC; Arulanandam R; Diallo JS
Front Immunol; 2023; 14():1181014. PubMed ID: 37153626
[TBL] [Abstract] [Full Text] [Related]
19. Advances in the application of immune checkpoint inhibitors in gynecological tumors.
Zou Y; Xu Y; Chen X; Zheng L
Int Immunopharmacol; 2023 Apr; 117():109774. PubMed ID: 37012881
[TBL] [Abstract] [Full Text] [Related]
20. car-T Cells in the treatment of ovarian cancer: A Promising Cell Therapy.
Zhang XW; Wu YS; Xu TM; Cui MH
Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979400
[TBL] [Abstract] [Full Text] [Related]
[Next]